Market Overview:
The global venous thromboembolism (VTE) therapeutics market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing incidence of VTE, rising geriatric population and technological advancements in VTE therapies. However, high cost associated with treatment and lack of awareness about VTE are some factors that may restrain the growth of this market during the forecast period. Based on type, the deep vein thrombosis (DVT) segment is estimated to account for a major share of the global venous thromboembolism (VTE) therapeutics market in 2018. This can be attributed to increasing incidence rates of DVT across the globe. The pulmonary embolism (PE) segment is projected to grow at a higher CAGR during the forecast period owing to increase in prevalence rates PE globally. Based on application, hospitals are estimated account for majority share of Venous Thromboembolism Therapeutics Market by 2030 end followed ambulatory surgery centers research institutes and others respectively .
Product Definition:
Venous thromboembolism (VTE) is a condition that results when a blood clot forms in one of the veins in your body, most often in your leg. This can block the flow of blood to the rest of your body. VTE can cause pain and swelling in your leg and can be dangerous if the clot breaks free and travels to your lungs, where it becomes lodged (called a pulmonary embolism).
Deep Vein Thrombosis(DVT):
Deep vein thrombosis (DVT) is a blood clot that forms in the deep veins of the body, which may cause swelling and pain in the affected area. DVT usually affects the legs; it can also occur in other parts of the body such as arms or lungs. The risk factors for developing DVT include immobility, obesity, pregnancy, and age above 40 years.
Pulmonary Embolism(PE):
Pulmonary embolism is a condition wherein there is formation of blood clots in the lungs. The major symptoms associated with this condition are shortness of breath, wheezing, and cough due to rising pulmonary congestion along with fever and other systemic symptoms. Pulmonary embolism can be differentiated from pulmonary hypertension which has similar clinical features but different underlying physiology.
Application Insights:
Based on application, the global venous thromboembolism (VTE) therapeutics market is segmented into hospital, ambulatory surgery centers, research institutes and others. The hospital segment dominated the market in 2017 owing to factors such as increasing prevalence of VTE and rising awareness among patients regarding treatment. According to a study published by WHO in 2018, around 10 million people develop VTE annually which results in approximately 150,000 deaths globally. DVT is one of the most common types of VTE while PE is relatively rarer than DVT.
The research institutes segment is expected to witness lucrative growth over the forecast period due to growing initiatives by various governments towards improving healthcare infrastructure at a national level including developing new diagnostic facilities for early diagnosis and effective treatment options for all forms of venous thromboembolism (VTE).
Regional Analysis:
North America dominated the global market in terms of revenue with a share of over 40.0% in 2017. This is due to the high incidence rate of VTE and its treatment, rising geriatric population, and increasing healthcare expenditure in this region. Moreover, introduction of innovative therapies for venous disorders such as Pulmonary Embolism Therapy (PETh) that combine anticoagulant therapy with low-cost devices used for mechanical ventilation are expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to an increase in healthcare expenditure by countries like China & Japan along with rise in awareness about prevention & treatment methods especially among patients suffering from obesity or diabetes which are major risk factors associated with VTEs.
Growth Factors:
- Increasing incidence of venous thromboembolism (VTE) due to rising prevalence of risk factors such as obesity, smoking, and advancing age
- Growing demand for novel oral anticoagulants (NOACs) and increasing use of prophylactic therapies to prevent VTE in high-risk patients
- Rising awareness about the symptoms and risk factors associated with VTE among patients and healthcare professionals
- Technological advancements in the diagnosis and treatment of VTE that are helping to improve patient outcomes
- Growing number of clinical studies evaluating new therapeutic agents for the treatment or prevention of VTE
Scope Of The Report
Report Attributes
Report Details
Report Title
Venous thromboembolism(VTE)Therapeutics Market Research Report
By Type
Deep Vein Thrombosis(DVT), Pulmonary Embolism(PE), Others
By Application
Hospital, Ambulatory Surgery Centers, Research Institutes, Others
By Companies
Boehringer Ingelheim, Bayer, Janssen, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo, Portola Pharmaceuticals, Armetheon
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
164
Number of Tables & Figures
115
Customization Available
Yes, the report can be customized as per your need.
Global Venous thromboembolism(VTE)Therapeutics Market Report Segments:
The global Venous thromboembolism(VTE)Therapeutics market is segmented on the basis of:
Types
Deep Vein Thrombosis(DVT), Pulmonary Embolism(PE), Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Ambulatory Surgery Centers, Research Institutes, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Boehringer Ingelheim
- Bayer
- Janssen
- Bristol-Myers Squibb
- Pfizer
- Daiichi-Sankyo
- Portola Pharmaceuticals
- Armetheon
Highlights of The Venous thromboembolism(VTE)Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Deep Vein Thrombosis(DVT)
- Pulmonary Embolism(PE)
- Others
- By Application:
- Hospital
- Ambulatory Surgery Centers
- Research Institutes
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Venous thromboembolism(VTE)Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Venous thromboembolism (VTE) is a condition in which blood clots form in the veins. These clots can travel to the lungs and cause serious problems, such as pulmonary embolism (PE), which is a blockage of air flow from the lungs to other parts of the body. VTE therapies are used to prevent or treat VTE.
Some of the major players in the venous thromboembolism(vte)therapeutics market are Boehringer Ingelheim, Bayer, Janssen, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo, Portola Pharmaceuticals, Armetheon.
The venous thromboembolism(vte)therapeutics market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Venous thromboembolism(VTE)Therapeutics Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Venous thromboembolism(VTE)Therapeutics Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Venous thromboembolism(VTE)Therapeutics Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Venous thromboembolism(VTE)Therapeutics Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Venous thromboembolism(VTE)Therapeutics Market Size & Forecast, 2020-2028 4.5.1 Venous thromboembolism(VTE)Therapeutics Market Size and Y-o-Y Growth 4.5.2 Venous thromboembolism(VTE)Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Deep Vein Thrombosis(DVT)
5.2.2 Pulmonary Embolism(PE)
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Ambulatory Surgery Centers
6.2.3 Research Institutes
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Venous thromboembolism(VTE)Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Venous thromboembolism(VTE)Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Deep Vein Thrombosis(DVT)
9.6.2 Pulmonary Embolism(PE)
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Ambulatory Surgery Centers
9.10.3 Research Institutes
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Deep Vein Thrombosis(DVT)
10.6.2 Pulmonary Embolism(PE)
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Ambulatory Surgery Centers
10.10.3 Research Institutes
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Deep Vein Thrombosis(DVT)
11.6.2 Pulmonary Embolism(PE)
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Ambulatory Surgery Centers
11.10.3 Research Institutes
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Deep Vein Thrombosis(DVT)
12.6.2 Pulmonary Embolism(PE)
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Ambulatory Surgery Centers
12.10.3 Research Institutes
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Deep Vein Thrombosis(DVT)
13.6.2 Pulmonary Embolism(PE)
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Ambulatory Surgery Centers
13.10.3 Research Institutes
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Venous thromboembolism(VTE)Therapeutics Market: Competitive Dashboard
14.2 Global Venous thromboembolism(VTE)Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Boehringer Ingelheim
14.3.2 Bayer
14.3.3 Janssen
14.3.4 Bristol-Myers Squibb
14.3.5 Pfizer
14.3.6 Daiichi-Sankyo
14.3.7 Portola Pharmaceuticals
14.3.8 Armetheon